Lucid Appoints Matthew Cox Among Its Board Of Directors.

E-mail Print PDF


Share

images69In an announcement made today by Lucid, Inc., the leader in FDA approved noninvasive cellular imaging, the company declared that Matthew C. Cox, Vice President of vRad, the world’s leading teleradiology provider, has been appointed to join the company`s Board of Directors. Lucid also announced that Mr.Cox is going to benefit the company with his huge experience in telemedicine. After joining the Board of Directors, Cox will raise the size of the Lucid Board’s members to eight.

Mr. Cox commented “I’m delighted to join Lucid’s Board as it begins the rollout of its FDA-cleared VivaScope® imaging technology and its VivaNet® telepathology system into private dermatology and dermatopathology practices. The combination of these two technologies can lower costs and reduce time-to-diagnosis for patients with suspicious skin lesions,” said Mr. Cox, he added “Lucid’s proprietary technologies provide a unique and enormous business opportunity in the telepathology space. I look forward to working with the Lucid management team to solidify noninvasive confocal imaging into the mainstream of dermatopathology.”Mr.Cox, during his career, has improved product revenues, profit margins and competitiveness, developed new business models and led product development groups. He also applied and improved corporate strategies from business concepts through deployment. Before vRad, Mr. Cox used to be the Director of Enterprise Solutions at Misys Healthcare. There he was responsible for customers and Misys enterprise-level products. Being and administrator for University Health System and a practice management/accounting consultant, he helped physicians, exercised maximizing performance in revenue growth, handled issues related to billing and compliance. He also has a B.S in Medical Humanities at Davidson College in Charlotte, N.C.

William Shea, Chairman of the Board of Directors at Lucid, said “Matt brings with him deep knowledge and experience that is directly relevant to Lucid, Specifically, Matt’s experiences in the critical real-world issues of running a telemedicine company and dealing with medical reimbursement and billing will be important assets to Lucid.” . Jay Eastman, CEO of Lucid, said , “Matt is a practical and results-oriented executive who has played a key management role in helping build the world’s leading teleradiology company” he added “Lucid has established itself as the leader in accurate, noninvasive assessment and diagnosis of melanoma and other skin cancers. The experience and track record that Matt brings to Lucid’s Board will greatly assist the management team in rapidly driving adoption of our platform to the benefit of patients, dermatologists, pathologists and ultimately our employees and shareholders.”


Share
These signals are relayed buying clomid online safe which then is by a number of such as medial preoptic and paraventricular nulcei.
javporn.cc